Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03377790
Other study ID # VP-102-101
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 21, 2018
Est. completion date November 26, 2018

Study information

Verified date December 2021
Source Verrica Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a Phase 3, randomized, double-blind, placebo-controlled, pivotal study to evaluate the safety and efficacy of VP-102 topical film-forming solution in subjects with Molluscum Contagiosum. VP-102 will be applied once every 21 days for up to 4 applications, to treatable molluscum contagiosum (molluscum) lesions on subjects 2 years and older. Efficacy will be assessed as the proportion of subjects achieving complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit.


Description:

This is a Phase 3, multi-center, randomized, double-blind, placebo (vehicle)-controlled, pivotal study that will be conducted in the United States to determine the efficacy and safety of VP-102 following treatment of molluscum lesions for up to 4 treatments, every 21 days, with VP-102/placebo in 250 subjects. Subjects will receive active VP-102 or placebo in a 3:2 ratio. Study drug (VP-102 or placebo) will be supplied in single-use applicators. The film-forming Study drug solution will be applied and left on the lesions for 24 hours before the subject and/or parents/guardian washes the lesions. Study drug may be removed prior to the 24-hour time point in the event treatment-emergent AEs are experienced. Molluscum lesions will be treated without occlusion in all anatomic areas including the face, trunk, back, arms, legs, hands, feet, anogenital region and buttocks.


Recruitment information / eligibility

Status Completed
Enrollment 266
Est. completion date November 26, 2018
Est. primary completion date November 26, 2018
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: To qualify for inclusion in this study, subjects must: 1. Be healthy subjects, at least 2 years of age or older. 2. Consent to having all molluscum lesions treated and the physician must be willing to treat all molluscum lesions initially present. Lesions within 10mm of the eyelid margins or the margin of any mucosal membrane should be evaluated carefully to ensure that they can be safely treated. Non-mucosal genital area lesions and inflamed lesions are considered treatable. 3. Be otherwise medically healthy with no clinically significant medical history as determined by the investigator. Subjects exhibiting active Atopic Dermatitis may be enrolled. 4. On day of treatment refrain from application of all topical agents including alcohol-based sanitary products and sunscreens for a minimum of 4 hours before Study drug application. Topical agents including alcohol-based sanitary products and sunscreens may be used after application of the study drug so long as they are not applied within 5cm of treated skin lesions. 5. Refrain from swimming, bathing or prolonged immersion in water or any liquids until the Study drug is removed. 6. Have the ability or have a guardian with the ability to follow study instructions and be likely to complete all study requirements. 7. Provide written informed consent or assent in a manner approved by the institutional review board (IRB) and/or have a parent/guardian provide written informed consent as evidenced by the signature on an IRB approved assent/consent form. 8. Provide written authorization for use and disclosure of protected health information. 9. Agree to allow photographs to be taken, (selected sites only) of selected lesions at every visit that will be used for training, publication and future marketing brochures. Exclusion Criteria: Subjects will be excluded from the study if they: 1. Are unable to cooperate with the requirements or visits of the study, as determined by the investigator. 2. Are systemically immunosuppressed or are receiving treatments such as chemotherapy or other non-topical immunosuppressive agents. 3. Have any lesions present at baseline in anatomic locations that the subject/parent/guardian or the physician is unwilling to treat. 4. Have had any previous treatment of molluscum including the use of cantharidin, antivirals, retinoids, curettage or freezing of lesions in the past 14 days. Additional treatments should not be implemented during the course of the study. 5. Have a history of illness or any dermatologic disorder which, in the opinion of the investigator, will interfere with accurate counting of lesions or increase the risk of adverse events. 6. History or presence of clinically significant medical, psychiatric, or emotional condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the data. 7. Have a history or presence of hypersensitivity or an idiosyncratic reaction to the Study drug or related compounds, or drug product excipients (acetone, ethyl alcohol, nitrocellulose, hydroxypropyl cellulose, castor oil, camphor, gentian violet, and denatonium benzoate). 8. Have a condition or situation that may interfere significantly with the subject's participation in the study (e.g., subjects who required hospitalization in the 2 months prior to screening for an acute or chronic condition including alcohol or drug abuse), at the discretion of the investigator. 9. Have received another investigational product within 14 days prior to the first application of the Study drug. 10. Have been treated within 14 days with a product that contains cantharidin (topical or homeopathic preparations) for any reason prior to screening. 11. Are sexually active or may become sexually active and are unwilling to practice responsible birth control methods. (e.g., combination of condoms and foam, birth control pills, intrauterine device, patch, shot and vaginal ring, etc.). Withdrawal is not an acceptable method of birth control. Females that have reached menarche must have a negative urine pregnancy test at each visit prior to treatment with Study drug. 12. Are pregnant or breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
VP-102 - Cantharidin, Topical Film Forming Solution
VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Up to 4 applications of VP-102 will be administered to Molluscum lesions at 21-day intervals.
Placebo -Topical Film Forming Solution without VP-102
Placebo a single-use drug device combination product containing only the vehicle. Up to 4 applications of Placebo will be administered to Molluscum lesions at 21-day intervals.

Locations

Country Name City State
United States Arlington Research Center Arlington Texas
United States Alabama Clinical Therapeutics Birmingham Alabama
United States Study Protocol, Inc., Boynton Beach Florida
United States Holston Medical Group Bristol Tennessee
United States Kings County Hospital Brooklyn New York
United States University North Carolina Dermatology Center Chapel Hill North Carolina
United States Clarkston Skin Research Clarkston Michigan
United States Skin Research Institute Coral Gables Florida
United States Southeastern Pediatric Associates Dothan Alabama
United States The Pediatric Associates of Fairfield, Inc Fairfield Ohio
United States Center for Skin Research Houston Texas
United States Midwest Children's Hospital Lincoln Nebraska
United States Applied Research Center of Arkansas Little Rock Arkansas
United States Summit Dermatology Oakbrook Terrace Illinois
United States ACRC Trials Plano Pediatrics Plano Texas
United States St Louis Children's Hospital Saint Louis Missouri
United States ASCLEPES Research Center Spring Hill Florida
United States Olympian Clinical Research Tampa Florida

Sponsors (4)

Lead Sponsor Collaborator
Verrica Pharmaceuticals Inc. Database Integrations, Inc., Instat Consulting, Inc., Paidion Research, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change From Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age. Change from Baseline to EOS Day 84 of the Composite Score From the Children's Dermatology Life Quality Index (CDLQI) Assessment at the EOS Visit to Measure the Quality of Life and Impact of Skin Disease in the Subset of Subjects 4 -16 Years of Age.
From responses to that questionnaire, a composite score was calculated. The calculated composite score was the sum of the individual 10 items of the CDLQI and could range from 0-30. For each item on the
CDLQI, a score of 0-3 was assigned using the following scores per response:
3: Very much (or Prevented School, Question 7 only)
2: Quite a lot
1: Only a little
0: Not at all Larger composite CDLQI scores indicate skin condition is having more effect on subjects' lives (worse outcome).
Baseline to Day 84 (EOS)
Other Percent Change of All Treatable Molluscum Lesions (Baseline and New) From Baseline at the EOS Visit Percent change of all treatable molluscum lesions (baseline and new) from baseline at the EOS visit. Day 1 (Baseline) compared to Day 84 (EOS)
Other Change From Baseline in the Number of Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. Change from baseline in the number of treatable molluscum lesions (baseline and new) at the EOS visit. Day 1 (Baseline) compared to Day 84 (EOS)
Other Percentage of Subjects Exhibiting a 75% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. Percentage of subjects that exhibited a 75% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. Day 1 (Baseline) compared to Day 84 (EOS)
Other Percentage of Subjects Exhibiting a 90% or Greater Reduction of All Treatable Molluscum Lesions (Baseline and New) at the EOS Visit. Percentage of subjects that exhibited a 90% or greater clearance of all treatable molluscum lesions (baseline and new) at the EOS visit. Day 1 (Baseline) compared to Day 84 (EOS)
Other Subject Reported Spread to Household Members as Measured by Any New Occurrence of Molluscum in Household Members of Subject. Subject reported spread to household members as measured by any new occurrence of molluscum in household members of subject. To be eligible for assessment, subjects had to have at least one household member free of lesions at baseline and have at least 1 post baseline assessment of spread of molluscum lesions. Days 1, 21, 42, 63 and 84 (EOS).
Primary Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 84 Visit (EOS) Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 84 visit (EOS). Day 1 (Baseline and new) compared to Day 84 (EOS)
Secondary Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 63 Visit Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 63 visit. Day 1 (Baseline and new) compared to Day 63
Secondary Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit. Day 1 (Baseline and new) compared to Day 42
Secondary Proportion of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 21 Visit Proportion of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 21 visit. Day 1 (Baseline and new) compared to Day 21
See also
  Status Clinical Trial Phase
Completed NCT03017846 - Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 Phase 2
Recruiting NCT05937672 - Cold Atmospheric Plasma Device Extension Study Phase 3
Completed NCT04535531 - A Phase 3 Molluscum Contagiosum Efficacy and Safety Study Phase 3
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT05897112 - Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum Phase 1
Withdrawn NCT05536882 - MC RCT - BPO vs Adapalene Phase 3
Completed NCT01348386 - Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum Phase 2/Phase 3
Completed NCT05634460 - Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum Phase 1
Completed NCT03186378 - Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Phase 2
Completed NCT03927716 - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) Phase 3
Recruiting NCT04476186 - The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children N/A
Completed NCT03927703 - A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC Phase 3
Completed NCT02665260 - Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03436615 - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum Phase 2
Recruiting NCT02759900 - Using a Cold Atmospheric Plasma Device to Treat Skin Disorders N/A
Completed NCT05680181 - Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Completed NCT03077750 - A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum Phase 2
Terminated NCT02024581 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03377803 - Cantharidin Application in Molluscum Patients Phase 3
Withdrawn NCT03336372 - Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients Early Phase 1